A Phase 2 interventional study of Tirzepatide and Placebo in Nonalcoholic Steatohepatitis, sponsored by Eli Lilly and Company. Completed at 112 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-24.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 82nd largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 192 in phase 2, and was the 317th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 62 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 190 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 3 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
Participants with or without type 2 diabetes mellitus (T2DM)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
Drug: Tirzepatide
10 mg tirzepatide administered SC once a week.
Drug: Tirzepatide
15 mg tirzepatide administered SC once a week.
Drug: Tirzepatide
Placebo administered SC once a week.
Drug: Placebo
Administered SC
Also known as: LY3298176
Administered SC
Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology
NASH resolution is defined as the absence of fatty liver disease or simple steatosis without steatohepatitis; the absence of hepatocellular ballooning (nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) 0 for ballooning); with or without mild lobular inflammation (NAS 0 or 1 for inflammation); and any value for steatosis. No worsening of fibrosis is defined as no increase in fibrosis stage from baseline to Week 52.
Time frame: Week 52
Percentage of Participants With ≥1 Point Decrease in Fibrosis Stage With No Worsening of NASH on Liver Histology
NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8 with the higher score indicating more aggressive disease. Evaluation of fibrosis stage was based on the nonalcoholic steatohepatitis clinical research network (NASH CRN) fibrosis staging system, which was scaled from 0 to 4 stages where, 0=None to 4=Cirrhosis. Participants were evaluated with the NASH CRN scoring system with ≥1-point reduction without worsening of NASH (defined as no increase in the NAS score).
Time frame: Week 52
Percentage of Participants With ≥1 Point Increase in Fibrosis Stage on Liver Histology
Participants were evaluated with the NASH CRN scoring system with ≥1 stage increase in fibrosis.
Time frame: Week 52
Percentage of Participants That Achieve a ≥2 Point Decrease in NAFLD (Non-alcoholic Fatty Liver Disease) Activity Score (NAS) on Liver Histology, With ≥1 Point Reduction in at Least 2 NAS Components
Hepatic histological improvement in NAS was defined as a decrease (improvement) in NAS by ≥ 2 with at least a 1-point reduction in at least 2 NAS components (lobular inflammation, hepatocellular ballooning or steatosis). The NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8, with the higher score indicating more aggressive disease.
Time frame: Week 52
Mean Absolute Change From Baseline in Liver Fat Content by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)
MRI-PDFF is an established method that enables quantification of fat content in the liver. The value of whole liver fat as assessed by MRI-PDFF is expressed in percentage (%) and ranges from 0 to 100% with higher values representing higher liver fat level. Least square (LS) mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: Variable = Baseline + Diabetes Flag (DIABFL) + REGION1 + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.
Time frame: Baseline to Week 52
Mean Change From Baseline in Body Weight
Change in body weight at the end of 52 weeks measured in kilogram (kg) using a calibrated scale. LS mean was calculated using MMRM model for post-baseline measures: Variable = Baseline + DIABFL + REGION1 + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.
Time frame: Baseline to Week 52
| Milestone | 5 Milligram (mg) Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Started | 47 | 47 | 48 | 48 |
| Received at least one dose of study drug | 47 | 47 | 48 | 48 |
| Completed | 40 | 44 | 43 | 38 |
| Not completed | 7 | 3 | 5 | 10 |
| Withdrew: Adverse event | 2 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 4 | 2 | 1 | 3 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 2 | 5 |
NASH resolution is defined as the absence of fatty liver disease or simple steatosis without steatohepatitis; the absence of hepatocellular ballooning (nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) 0 for ballooning); with or without mild lobular inflammation (NAS 0 or 1 for inflammation); and any value for steatosis. No worsening of fibrosis is defined as no increase in fibrosis stage from baseline to Week 52.
| Percentage of participants | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology | 51.84 | 63.13 | 73.92 | 12.62 |
NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8 with the higher score indicating more aggressive disease. Evaluation of fibrosis stage was based on the nonalcoholic steatohepatitis clinical research network (NASH CRN) fibrosis staging system, which was scaled from 0 to 4 stages where, 0=None to 4=Cirrhosis. Participants were evaluated with the NASH CRN scoring system with ≥1-point reduction without worsening of NASH (defined as no increase in the NAS score).
| Percentage of participants | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Percentage of Participants With ≥1 Point Decrease in Fibrosis Stage With No Worsening of NASH on Liver Histology | 59.21 | 53.35 | 54.3 | 32.51 |
Participants were evaluated with the NASH CRN scoring system with ≥1 stage increase in fibrosis.
| Percentage of participants | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Percentage of Participants With ≥1 Point Increase in Fibrosis Stage on Liver Histology | 12.04 | 9.81 | 5.53 | 13.03 |
Hepatic histological improvement in NAS was defined as a decrease (improvement) in NAS by ≥ 2 with at least a 1-point reduction in at least 2 NAS components (lobular inflammation, hepatocellular ballooning or steatosis). The NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8, with the higher score indicating more aggressive disease.
| Percentage of participants | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Percentage of Participants That Achieve a ≥2 Point Decrease in NAFLD (Non-alcoholic Fatty Liver Disease) Activity Score (NAS) on Liver Histology, With ≥1 Point Reduction in at Least 2 NAS Components | 81.02 | 86.55 | 88.77 | 38.09 |
MRI-PDFF is an established method that enables quantification of fat content in the liver. The value of whole liver fat as assessed by MRI-PDFF is expressed in percentage (%) and ranges from 0 to 100% with higher values representing higher liver fat level. Least square (LS) mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: Variable = Baseline + Diabetes Flag (DIABFL) + REGION1 + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.
| absolute percentage of liver fat | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Mean Absolute Change From Baseline in Liver Fat Content by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) | -10.12 ± 1.165 | -10.15 ± 1.071 | -11.34 ± 1.107 | -1.31 ± 1.142 |
Change in body weight at the end of 52 weeks measured in kilogram (kg) using a calibrated scale. LS mean was calculated using MMRM model for post-baseline measures: Variable = Baseline + DIABFL + REGION1 + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.
| Kilogram (kg) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Mean Change From Baseline in Body Weight | -11.46 ± 1.404 | -14.22 ± 1.380 | -17.88 ± 1.376 | -1.04 ± 1.392 |
Collected over Baseline Up to Week 56. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5 mg Tirzepatide | 0/47 (0%) | 5/47 (10.6%) | 43/47 (91.5%) |
| 10 mg Tirzepatide | 0/47 (0%) | 4/47 (8.5%) | 43/47 (91.5%) |
| 15 mg Tirzepatide | 0/48 (0%) | 0/48 (0%) | 44/48 (91.7%) |
| Placebo | 0/48 (0%) | 3/48 (6.3%) | 40/48 (83.3%) |
| Event | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Ovarian neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/27 | 0/26 | 0/29 | 1/27 |
| Endometrial thickeningReproductive system and breast disorders | 0/27 | 0/26 | 0/29 | 1/27 |
| Developmental hip dysplasiaCongenital, familial and genetic disorders | 1/47 | 0/47 | 0/48 | 0/48 |
| Large intestine polypGastrointestinal disorders | 0/47 | 1/47 | 0/48 | 0/48 |
| PneumoperitoneumGastrointestinal disorders | 0/47 | 1/47 | 0/48 | 0/48 |
| Umbilical herniaGastrointestinal disorders | 0/47 | 1/47 | 0/48 | 0/48 |
| CholecystitisHepatobiliary disorders | 0/47 | 1/47 | 0/48 | 0/48 |
| Covid-19 pneumoniaInfections and infestations | 1/47 | 0/47 | 0/48 | 0/48 |
| HypokalaemiaMetabolism and nutrition disorders | 1/47 | 0/47 | 0/48 | 0/48 |
| Transient ischaemic attackNervous system disorders | 1/47 | 0/47 | 0/48 | 0/48 |
| Event | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 17/47 | 16/47 | 21/48 | 6/48 |
| DiarrhoeaGastrointestinal disorders | 15/47 | 17/47 | 13/48 | 11/48 |
| ConstipationGastrointestinal disorders | 11/47 | 9/47 | 7/48 | 3/48 |
| Decreased appetiteMetabolism and nutrition disorders | 9/47 | 10/47 | 11/48 | 1/48 |
| Covid-19Infections and infestations | 5/47 | 6/47 | 9/48 | 4/48 |
| DyspepsiaGastrointestinal disorders | 2/47 | 8/47 | 2/48 | 2/48 |
| VomitingGastrointestinal disorders | 3/47 | 3/47 | 7/48 | 1/48 |
| Abdominal painGastrointestinal disorders | 6/47 | 3/47 | 4/48 | 3/48 |
| Abdominal pain upperGastrointestinal disorders | 6/47 | 2/47 | 0/48 | 2/48 |
| DizzinessNervous system disorders | 2/47 | 6/47 | 4/48 | 2/48 |
All randomized participants.
| Age, Continuous(years) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 55.00 ± 11.62 | 54.30 ± 12.08 | 54.90 ± 10.02 | 53.50 ± 11.60 | 54.40 ± 11.28 |
| Sex: Female, Male(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|---|
| Female | 27 | 26 | 29 | 27 | 109 |
| Male | 20 | 21 | 19 | 21 | 81 |
| Ethnicity (NIH/OMB)(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 19 | 15 | 17 | 18 | 69 |
| Not Hispanic or Latino | 21 | 25 | 27 | 24 | 97 |
| Unknown or Not Reported | 7 | 7 | 4 | 6 | 24 |
| Race (NIH/OMB)(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 1 | 0 | 3 |
| Asian | 5 | 6 | 6 | 5 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 0 | 1 |
| White | 41 | 39 | 41 | 43 | 164 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|---|
| Belgium | 0 | 0 | 1 | 0 | 1 |
| France | 7 | 7 | 2 | 6 | 22 |
| Israel | 3 | 2 | 0 | 0 | 5 |
| Italy | 1 | 0 | 2 | 3 | 6 |
| Japan | 4 | 4 | 4 | 4 | 16 |
| Mexico | 1 | 3 | 3 | 3 | 10 |
| Poland | 1 | 0 | 0 | 0 | 1 |
| Spain | 1 | 0 | 6 | 1 | 8 |
| United Kingdom | 1 | 5 | 4 | 4 | 14 |
| United States | 28 | 26 | 26 | 27 | 107 |
Showing the first 100 of 112 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Nov 2019 to primary completion in Dec 2023, 48 months.
Results were first posted in Jan 2025, 1 year 1 month after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 48 months is above that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide
Non-alcoholic Fatty Liver Disease →